Mira Pharmaceuticals Inc.
- Biotech or pharma, therapeutic R&D
Mira Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics for neuropsychiatric and neurological disorders. The company’s lead candidate, Ketamir-2, is a next-generation oral ketamine analog currently in a Phase 1 clinical trial for neuropathic pain, with ongoing exploration of additional indications including PTSD and depression. Designed to be a safer, non-psychoactive alternative to traditional ketamine, Ketamir-2 aims to deliver effective CNS treatment without the dissociative side effects. Mira is focused on advancing non-scheduled, accessible therapies supported by strong preclinical and clinical data.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}